Tenet Healthcare (NYSE: THC) reported Q3 EPS of $1.44, $0.18 better than the analyst estimate of $1.26. Revenue for the quarter came in at $4.8 billion versus the consensus estimate of $4.8 billion.

Board of Directors has authorized a $1 billion share repurchase program.

GUIDANCE:

FY 2022 Adjusted EBITDA Outlook range revised to $3.375 billion to $3.475 billion, a ~1% change to the mid-point of the previous Outlook range

For earnings history and earnings-related data on Tenet Healthcare (THC) click here.